Evidence map›Paper›PMID 39918749›Full record

ArticleAnnals of surgical oncology2025

The American Joint Committee on Cancer (AJCC) Breast Cancer Staging, Eighth Edition, is more Reflective of Cancer Biology than the Seventh Edition.

Jessica Young, Mariko Asaoka, Farhad Ghasemi, Kohei Chida, Arya Mariam Roy, Li Yan, Kenichi Hakamada, Kazuaki Takabe

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jessica Young *Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Mariko Asaoka *Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Farhad GhasemiDepartment of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Kohei ChidaDepartment of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Arya Mariam RoyDepartment of Hematology and Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Li YanDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Kenichi HakamadaDepartment of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Kazuaki TakabeDepartment of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. kazuaki.takabe@roswellpark.org.ORCID http://orcid.org/0000-0002-6435-4241

Funding

Impact of Circulating Myeloid Cell Clusters on Anti-Tumor ImmunityR01CA250412 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ABRAMS, SCOTT I., EVANS, SHARON S · 2021 to 2025
$3.4M
Functional Significance of individual p53 mutations in determining the role of estrogen receptor beta in triple negative breast cancerR01CA251545 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI DAS, GOKUL M. · 2021 to 2025
$2.9M
Leveraging the GTP Biosynthetic Pathway for Anti-Tumor TherapiesR37CA248018 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Anna Bianchi-Smiraglia · 2021 to 2026
$2.3M
Multiparametric photoacoustic and ultrasonic imaging of the breast in cranial-caudal viewR01EB029596 · NIBIB · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI XIA, JUN · 2020 to 2023
$1.4M
NIH HHS R01CA250412NIH HHS R01CA251545NIH HHS R01EB029596NIH HHS R37CA248018U.S. Department of Defense W81XWH-19-1-0111U.S. Department of Defense W81XWH-19-1-0674
6 · The paper itself

Abstract

backgroundThe American Joint Committee on Cancer (AJCC) eighth-edition breast cancer staging system incorporating tumor grade, hormone/human epidermal growth factor receptor 2 (HER2) receptor status, and genomic assays has demonstrated better prognostic value than the seventh edition. Given the crucial role of cancer biology in prognosis, the authors hypothesized that the AJCC eighth-edition criteria offer better biologic differentiation between stages than the seventh edition.

methodsThis study analyzed 696 breast cancer patients from The Cancer Genome Atlas (TCGA) and Text Information Extraction System (TIES) database, with complete information available for staging according to both the AJCC seventh- and eighth-edition criteria.

resultsThe study indicated an increase in the number of patients classified as stage I in the eighth edition compared with the seventh edition, particularly in hormone-positive breast cancers. Furthermore, the eighth edition demonstrated improved discrimination in overall survival between stages I and II cancers. The eighth edition was able to distinguish significant differences in cell proliferation, intratumor heterogeneity, homologous recombination deficiency, and neoantigen load between stages I and II cancers. Moreover, the eighth edition more clearly differentiated immune cell infiltration between stages II and I cancer than the seventh edition. Finally, immune activity and gene expression of immune checkpoints such as PDCD1, PDL1, CTLA4, LAG3, TIGIT, and IDO1 and 2 showed a more pronounced difference between stages I and II cancers in the eighth edition than in the seventh edition.

conclusionThe AJCC eighth edition breast cancer staging system better distinguishes cancers with more aggressive biology than the seventh edition.

Indexed as

Biomarkers, TumorBreast NeoplasmsNeoplasm StagingErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoplasm GradingPrognosisSurvival RateBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.